Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Hypertension Research

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Cardiology

Show all topics

DOI

10.1038/s41440-024-01725-4